Morgan Stanley analyst Sean Laaman resumes coverage on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with a Overweight rating and a price ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments Hot New Coverage New Coverage